Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center-Reference-Cited by-同舟云学术

Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center

Published:2020-08-15 Issue:16 Volume:59 Page:1963-1970
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Takai Chinatsu¹,Ito Satoshi¹,Kobayashi Daisuke¹²,Nemoto Tetsuya¹³,Lee Hyunho¹⁴,Abe Asami¹,Otani Hiroshi¹,Nakazono Kiyoshi¹,Murasawa Akira¹,Ishikawa Hajime¹

Affiliation:

1. Department of Rheumatology, Niigata Rheumatic Center, Japan

2. Division of Clinical Nephrology and Rheumatology Niigata University Graduate School of Medical and Dental Sciences, Japan

3. Department of Orthopaedic Surgery, Showa University School of Medicine, Japan

4. Department of Orthopaedic Surgery, Nihon University School of Medicine, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/59/16/59_3934-19/_pdf

Reference19 articles.

1. 1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 4: 1932-1939, 1999.

2. 2. van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 56: 2129-2134, 2007.

3. 3. Tanaka Y, Takeuchi T, Mimori T, et al.; RRR study investigators. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69: 1286-1291, 2010.

4. 4. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48, 1995.

5. 5. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 25: 659-662, 1949.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis;Expert Opinion on Biological Therapy;2024-07-25

2. Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review;Arthritis Research & Therapy;2023-11-20

3. Erratum for Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center;Internal Medicine;2021-05-01

4. Methotrexate;Reactions Weekly;2020-10